Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Carpenter, W. T. Articles by Summerfelt, A. T. Search for Related Content PubMed Citation Articles by Carpenter, W. T., Jr. Articles by Summerfelt, A. T. Other Neuroleptics

Comparative Effectiveness of Fluphenazine Decanoate Injections Every 2 Weeks Versus Every 6 Weeks

OBJECTIVE: Dose reduction strategies for the maintenance treatment of schizophrenia are designed to maintain the benefits of antipsychotic drug therapy while reducing risks. Previous strategies with decanoate preparations have been based on the use of lower doses per injection to achieve dose reduction; these strategies have achieved dose reduction but have resulted in some increase in symptoms. The authors tested a new dose reduction approach: increasing the interval between injections during intramuscular decanoate antipsychotic treatment. METHOD: Fifty outpatients with schizophrenia or schizoaffective disorder were randomly assigned to receive 25 mg of fluphenazine decanoate intramuscularly either every 2 weeks or every 6 weeks for 54 weeks in a double-blind design. RESULTS: The two dose regimens did not differ significantly in relapse, symptom, or side effect measures. The every-6-weeks regimen was associated with a significant reduction in total antipsychotic exposure. CONCLUSIONS: The use of injections every 6 weeks instead of every 2 weeks may increase compliance and improve patients' comfort as well as decrease cumulative antipsychotic exposure, without increasing relapse rates or symptoms. (Am J Psychiatry 1999; 156:412–418)

This article has been cited by other articles:

				D. Taylor Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review The British Journal of Psychiatry, November 1, 2009; 195(52): S13 - S19. [Abstract] [Full Text] [PDF]

				A.-N. Samaha, P. Seeman, J. Stewart, H. Rajabi, and S. Kapur "Breakthrough" Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time J. Neurosci., March 14, 2007; 27(11): 2979 - 2986. [Abstract] [Full Text] [PDF]

				M. X. Patel and A. S. David Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv. Psychiatr. Treat., May 1, 2005; 11(3): 203 - 211. [Abstract] [Full Text] [PDF]

				M. Gitlin, K. Nuechterlein, K. L. Subotnik, J. Ventura, J. Mintz, D. L. Fogelson, G. Bartzokis, and M. Aravagiri Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia Focus, January 1, 2004; 2(1): 122 - 130. [Abstract] [Full Text] [PDF]

				J. M. Kane, J. M. Davis, N. Schooler, S. Marder, D. Casey, B. Brauzer, J. Mintz, and R. Conley A Multidose Study of Haloperidol Decanoate in the Maintenance Treatment of Schizophrenia Am J Psychiatry, April 1, 2002; 159(4): 554 - 560. [Abstract] [Full Text] [PDF]

				M. Gitlin, K. Nuechterlein, K. L. Subotnik, J. Ventura, J. Mintz, D. L. Fogelson, G. Bartzokis, and M. Aravagiri Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia Am J Psychiatry, November 1, 2001; 158(11): 1835 - 1842. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us